Literature DB >> 17349793

Synthesis and evaluation of 2-(2,6-dihalophenyl)-3-pyrimidinyl-1,3-thiazolidin-4-one analogues as anti-HIV-1 agents.

Ravindra K Rawal1, Rajkamal Tripathi, S B Katti, Christophe Pannecouque, Erik De Clercq.   

Abstract

A series of 2-(2,6-dihalophenyl)-3-(substituted pyrimidinyl)-1,3-thiazolidin-4-ones were designed on the prediction of quantitative structure-activity relationship (QSAR) studies, synthesized, and evaluated as HIV-1 reverse transcriptase inhibitors. Our attempts in correlating the identified molecular surface features related properties for modeling the HIV-1 RT inhibitory activity resulted in some statistically significant QSAR models with good predictive ability. The results showed that compounds 4m and 4n were highly active in inhibiting HIV-1 replication with EC(50) values in the range of 22-28 nM in MT-4 as well as in CEM cells with selectivity indexes of >10,000. The derived models collectively suggest that the compounds should be compact without bulky substitution on its peripheries for better HIV-1 RT inhibitory activity. These models also indicate a preference for hydrophobic compounds to obtain good HIV-1 RT inhibitory activity.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17349793     DOI: 10.1016/j.bmc.2007.02.044

Source DB:  PubMed          Journal:  Bioorg Med Chem        ISSN: 0968-0896            Impact factor:   3.641


  11 in total

1.  Convenient diastereoselective synthesis of annulated 3-substituted-(5S*,6S*,Z)-2-(2-(2,4-dinitrophenyl)hydrazono)-5,6-diphenyl-1,3-thiazinan-4-ones.

Authors:  Alaa A Hassan; Nasr K Mohamed; Ashraf A Aly; Hendawy N Tawfeek; Henning Hopf; Stefan Bräse; Martin Nieger
Journal:  Mol Divers       Date:  2019-01-03       Impact factor: 2.943

2.  Sonochemical synthesis of pyrido[2,3-d:6,5-d']-dipyrimidines catalyzed by [HNMP]+[HSO4]- and their antimicrobial activity studies.

Authors:  Hossein Naeimi; Asieh Didar; Zahra Rashid; Zohreh Zahraie
Journal:  J Antibiot (Tokyo)       Date:  2017-04-26       Impact factor: 2.649

3.  Design, synthesis and antimicrobial evaluation of novel 2-aryl-thiazolidin-4-one derivatives.

Authors:  Davinder Prasad; Awanit Kumar; Praveen Kumar Shukla; Mahendra Nath
Journal:  Org Med Chem Lett       Date:  2011-08-03

4.  Microwave-assisted synthesis of a novel class of imidazolylthiazolidin-4-ones and evaluation of its biological activities.

Authors:  Sachin G Modha; Vaibhav P Mehta; Denis Ermolat'ev; Jan Balzarini; Kristof Van Hecke; Luc Van Meervelt; Erik Van der Eycken
Journal:  Mol Divers       Date:  2010-01-19       Impact factor: 3.364

5.  Design, synthesis and in silico screening of benzoxazole-thiazolidinone hybrids as potential inhibitors of SARS-CoV-2 proteases.

Authors:  Vijay Sai Krishna Cheerala; Prasanth Ghanta; Sundaresan Chittor Neelakantan
Journal:  RSC Adv       Date:  2021-12-10       Impact factor: 4.036

6.  Novel 4-Thiazolidinone Derivatives as Anti-Infective Agents: Synthesis, Characterization, and Antimicrobial Evaluation.

Authors:  Amit Gupta; Rajendra Singh; Pankaj K Sonar; Shailendra K Saraf
Journal:  Biochem Res Int       Date:  2016-01-26

Review 7.  Chemistry of Substituted Thiazinanes and Their Derivatives.

Authors:  Alaa A Hassan; Stefan Bräse; Ashraf A Aly; Hendawy N Tawfeek
Journal:  Molecules       Date:  2020-11-28       Impact factor: 4.411

8.  Facile preparation and conversion of 4,4,4-trifluorobut-2-yn-1-ones to aromatic and heteroaromatic compounds.

Authors:  Takashi Yamazaki; Yoh Nakajima; Minato Iida; Tomoko Kawasaki-Takasuka
Journal:  Beilstein J Org Chem       Date:  2021-01-15       Impact factor: 2.883

9.  Non-nucleoside inhibitors of the hepatitis C virus NS5B RNA-dependant RNA polymerase: 2-aryl-3-heteroaryl-1,3-thiazolidin-4-one derivatives.

Authors:  Ravindra K Rawal; S B Katti; Neerja Kaushik-Basu; Payal Arora; Zhenhua Pan
Journal:  Bioorg Med Chem Lett       Date:  2008-10-08       Impact factor: 2.823

10.  Synthesis and biological activity evaluation of 5-pyrazoline substituted 4-thiazolidinones.

Authors:  Dmytro Havrylyuk; Borys Zimenkovsky; Olexandr Vasylenko; Craig W Day; Donald F Smee; Philippe Grellier; Roman Lesyk
Journal:  Eur J Med Chem       Date:  2013-06-06       Impact factor: 6.514

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.